Hepatocellular Carcinoma Resectable
Conditions
Keywords
VTRNA2-1 promoter, recurrence, methylation
Brief summary
The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.
Detailed description
This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number.
Interventions
None listed
Sponsors
Chang Gung Memorial Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Inclusion criteria
subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies
Exclusion criteria
history of different malignant disease. subjects cannot be treated with curative surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival (DFS) | a month | The length of time from curative hepatectomies treatment and recurrence or mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | a month | The length of time from hepatectomies treatment for HCC and still alive. |
Countries
Taiwan
Outcome results
None listed